VIDEO: Directional deep brain stimulation: novel treatment options for all Parkinson’s patients
sponsored by Boston Scientific
Author: SPONSOREDPublished: 4 October 2017
Prep: Cook: Serves:
Watch deep brain stimulation (DBS) experts Professor Pollo, Professor Timmermann, Professor Visser-Vanderwalle and Professor Volkmann explain the benefits of novel directional DBS systems for improved symptom control and fewer side effects
Every human brain is unique and every course of Parkinson’s disease has its own characteristics. In deep brain stimulation (DBS) therapy, physicians aim to target a very specific part of the brain – the subthalamic nucleus – in order to mitigate Parkinson’s symptoms.
Up until now, conventional DBS systems only allowed for stimulation with ring electrodes. With these electrodes, stimulation took the form of a ring around the electrode in the lead that was implanted into the patient’s brain. This meant that while physicians tried to target a very specific area of the brain, they always ran the risk of stimulating its neighbouring regions – since they could not steer the stimulation precisely. Unintended and unwanted stimulation could cause side effects such as speech problems.
The latest generation of DBS devices allow physicians to precisely steer the stimulation to target one specific area of the brain – significantly reducing side effects from unwanted stimulation. Our directional DBS systems use novel lead designs with segmented electrodes that allow the activation of individual electrode contacts. In addition, the technology in the pulse generator that powers the leads – the Multiple Independent Current Control (MICC) technology – allows the physician to specify exactly the amount of current needed for every contact of the electrode.
Through activating specific electrode contacts, and defining the amount of stimulation for each contact, stimulation precision is significantly increased. It is similar to shining a light on a specific spot with a flashlight. With the new systems, physicians now have full control of the stimulation steering and an increased set of stimulation options.
About deep brain stimulation (DBS) therapy
DBS uses a stimulator that is implanted into the patient’s chest. The stimulator sends mild electrical impulses to specific areas of the brain via thin wires called leads. This stimulation may help improve day-to-day experiences for people living with movement disorders such as Parkinson’s disease, dystonia, or essential tremor.
For comprehensive information on deep brain stimulation and Parkinson’s, please visit the EPDA website.
This article is sponsored by Boston Scientific. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
2015 campaign focuses on building ‘carer-friendly communities’
2 weeks ago
EPDA signs new charter on workplace rights
The European Parkinson’s Disease Association (EPDA) has signed the Dying to Work Charter – a pledge protecting the workplace rights of people with serious conditions. The charter – part of the Trade Union Congress’ wider Dying to Work campaign – has so far protected over half a million workers in the UK. The Dying to Work campaign group, chaired by MEP Rory Palmer, is calling on the European Union to amend its current legislation. The campaign is asking for serious conditions to be identified as a ‘protected characteristic’ – meaning employees would enjoy a protected period after diagnosis which would ensure the couldn’t be unfairly dismissed. Russell Patten, secretary general at the EPDA, said: “At the EPDA, we are committed to improving employment conditions, reducing stigma and ensuring accessibility to essential services for all people with Parkinson’s disease.” Image: Rory Palmer MEP (left) and Russell Patten, secretary general at the EPDA…
Scientists at the National University of Ireland Galway have created a wearable device that they believe will help people with Parkinson’s to walk more easily. The device, named cueStim, is worn around the waist and delivers fixed rhythmic sensory stimulation to the wearer. This will counteract ‘freezing of gait’ symptoms that are often experienced by people living with the condition. The scientists collaborated with professionals from UK medical board NHS Greater Glasgow and Clyde to test the device, and found that it significantly reduced the time taken for a person with Parkinson’s to complete walking tasks. Gearóid Ó Laighin, professor of electrical engineering at NUI Galway, said: “We are now seeking additional clinical partners to work with NUI Galway in carrying out a comprehensive long-term clinical evaluation of cueStim in enhancing the quality of life of people with Parkinson’s disease through a funded programme of research.”
Could robots replace animals in Parkinson’s medical trials?
Researchers at Heriot-Watt University, Edinburgh, UK, are testing new treatments for Parkinson’s disease on robots. Academics at the university – who are collaborating with the International Institute for Neurosciences of Natal, Brazil – will use computer models of the human brain to simulate the effect medication has on people living with Parkinson’s. The study – which is the first of its kind – could lead to a major shift in the way that Parkinson’s treatments are tested in the future, and potentially put an end to animal testing. Dr Patricia A Vargas, the lead collaborator of the study said: “Our hope is two-fold – to reduce and replace animals in research, and to help and inform new therapies, treatments and even the cure for this debilitating disease.”